These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regulation of the human immune response in tuberculosis. Tsuyuguchi I Infect Agents Dis; 1996 Mar; 5(2):82-97. PubMed ID: 8721045 [No Abstract] [Full Text] [Related]
3. The recombinant tuberculosis vaccine rBCG ΔureC::hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells. Farinacci M; Weber S; Kaufmann SH Vaccine; 2012 Dec; 30(52):7608-14. PubMed ID: 23088886 [TBL] [Abstract][Full Text] [Related]
4. Protective immunity of recombinant Mycobacterium bovis BCG expressing rhomboid gene against Eimeria tenella challenge. Wang Q; Li J; Zhang X; Liu Q; Liu C; Ma G; Cao L; Gong P; Cai Y; Zhang G Vet Parasitol; 2009 Mar; 160(3-4):198-203. PubMed ID: 19117681 [TBL] [Abstract][Full Text] [Related]
5. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Martin C; Williams A; Hernandez-Pando R; Cardona PJ; Gormley E; Bordat Y; Soto CY; Clark SO; Hatch GJ; Aguilar D; Ausina V; Gicquel B Vaccine; 2006 Apr; 24(17):3408-19. PubMed ID: 16564606 [TBL] [Abstract][Full Text] [Related]
6. Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein. Mukai T; Maeda Y; Tamura T; Matsuoka M; Tsukamoto Y; Makino M J Immunol; 2009 Nov; 183(10):6561-8. PubMed ID: 19846882 [TBL] [Abstract][Full Text] [Related]
7. Mycobacterium-specific human CD8 T cell responses. Klein MR; Fox A Arch Immunol Ther Exp (Warsz); 2001; 49(5):379-89. PubMed ID: 11798136 [TBL] [Abstract][Full Text] [Related]
8. Rational vaccine development--a new trend in tuberculosis control. Kaplan G N Engl J Med; 2005 Oct; 353(15):1624-5. PubMed ID: 16221789 [No Abstract] [Full Text] [Related]
9. Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette Guerin vaccine or Mycobacterium tuberculosis infection. Ryan AA; Nambiar JK; Wozniak TM; Roediger B; Shklovskaya E; Britton WJ; Fazekas de St Groth B; Triccas JA J Immunol; 2009 Jun; 182(11):7172-7. PubMed ID: 19454714 [TBL] [Abstract][Full Text] [Related]
10. The Achilles heel of BCG. Orme IM Tuberculosis (Edinb); 2010 Nov; 90(6):329-32. PubMed ID: 20659816 [TBL] [Abstract][Full Text] [Related]
11. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518 [TBL] [Abstract][Full Text] [Related]
12. Current tuberculosis vaccine development. Young DB Clin Infect Dis; 2000 Jun; 30 Suppl 3():S254-6. PubMed ID: 10875794 [TBL] [Abstract][Full Text] [Related]
13. Mouse and guinea pig models for testing new tuberculosis vaccines. Orme IM Tuberculosis (Edinb); 2005; 85(1-2):13-7. PubMed ID: 15687022 [TBL] [Abstract][Full Text] [Related]
14. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts. Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y; Xing Z Mol Ther; 2006 Apr; 13(4):766-75. PubMed ID: 16343993 [TBL] [Abstract][Full Text] [Related]
15. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250 [TBL] [Abstract][Full Text] [Related]
16. More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4. Qie YQ; Wang JL; Liu W; Shen H; Chen JZ; Zhu BD; Xu Y; Zhang XL; Wang HH Scand J Immunol; 2009 Apr; 69(4):342-50. PubMed ID: 19284499 [TBL] [Abstract][Full Text] [Related]
17. Challenges and solutions for a rational vaccine design for TB-endemic regions. Gowthaman U; Mushtaq K; Tan AC; Rai PK; Jackson DC; Agrewala JN Crit Rev Microbiol; 2015; 41(3):389-98. PubMed ID: 24495096 [TBL] [Abstract][Full Text] [Related]
18. Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A. Sugawara I; Udagawa T; Taniyama T Tuberculosis (Edinb); 2007 Mar; 87(2):94-101. PubMed ID: 16815096 [TBL] [Abstract][Full Text] [Related]
19. Current progress in tuberculosis vaccine development. Orme IM Vaccine; 2005 Mar; 23(17-18):2105-8. PubMed ID: 15755579 [TBL] [Abstract][Full Text] [Related]
20. Maintenance of CD8(+) T-cell memory following infection with recombinant sindbis and vaccinia viruses. Villacres MC; Zuo J; Bergmann CC Virology; 2000 Apr; 270(1):54-64. PubMed ID: 10772979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]